Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas

Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 8, 2023 /PRNewswire/ — Estrella Biopharma, Inc. (“Estrella”), a biopharmaceutical company whose mission is to harness the evolutionary power of the human…